Skip to main content
Premium Trial:

Request an Annual Quote

Karius Raises $165M in Series B Financing Round

NEW YORK – Infectious disease diagnostic firm Karius has raised $165 million in a Series B financing round led by SoftBank Vision Fund 2.

The Redwood City, California-based firm will use the funding to expand access to its microbial cell-free DNA technology to help doctors diagnose infectious diseases. Karius will also use the money to broaden clinical development and accelerate technology innovation.

The funding round also included new investors General Catalyst and HBM Healthcare Investments, as well as existing ventures Khosla Ventures and Lightspeed Venture Partners.

According to Karius, its sequencing technology integrates novel genomics and artificial intelligence approaches to detect and measure microbial cell-free DNA of more than 1,000 clinically relevant pathogens from a single blood sample. The firm believes that its test will help advise doctors as to the likely types and quantities of infectious microorganisms affecting their patients.

Karius said that the assay normally delivers next-day results.

"This transformative round will allow Karius to help more patients faster, fuel the next wave of clinical studies, and accelerate technology innovation," Karius CEO Mickey Kertesz said in a statement.

Karius previously raised $50 million in a Series A financing found in 2017.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.